Compound News and Research

RSS

Redesigned vancomycin can kill deadliest antibiotic-resistant bacteria

A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria.

25 Aug 2011

Scientists identify cellular protein that plays a critical role in Ebola virus infection

Research published by two teams of Army scientists and collaborators has identified a cellular protein that plays a critical role in Ebola virus infection.

25 Aug 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

No effective treatment yet for acute lung injury

Patients can essentially drown in their own fluids when trauma and infection prompt blood vessels to leak, flooding millions of air sacs in their lungs.

22 Aug 2011

New technique can detach sugars from carrier molecule, reattach them to drugs

The surface of cells and many biologically active molecules are studded with sugar structures that are not used to store energy, but rather are involved in communication, immunity and inflammation.

22 Aug 2011

Scientists discover mechanism that helps explain why stress causes DNA damage

For years, researchers have published papers that associate chronic stress with chromosomal damage. Now researchers at Duke University Medical Center have discovered a mechanism that helps to explain the stress response in terms of DNA damage.

22 Aug 2011

VOA News examines new drug compound that shows broad-based efficacy in lab tests

VOA News looks at a new drug compound developed by researchers at the Massachusetts Institute of Technology (MIT) that they say has so far "killed every virus it's been tested on in the laboratory." "The drug - known by the acronym DRACO - works by chemically targeting viral-infected cells and prompting them to self-destruct, eliminating the disease in the process," VOA writes.

20 Aug 2011

Researchers turn their attention to Chagas disease as developed countries see rise in infection rates

Chagas disease, a historically neglected tropical disease that the WHO estimates affects about 10 million people worldwide, is drawing increased attention as infection by the parasite spreads from Latin America to developed countries, such as Spain and the United States, Science reports.

20 Aug 2011

Seven research teams across the U.S. to develop new drugs for nervous system disorders

The National Institutes of Health has made awards to investigators across the United States for an ambitious set of projects seeking to develop new drugs for disorders of the nervous system.

19 Aug 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

AMRI today announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.

19 Aug 2011

Cortex second quarter net loss decreases to $356,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.

18 Aug 2011

IU scientist to investigate salubrinal drug against osteoporosis

An Indiana University scientist studying human bone growth has received a $2.6 million grant from the U.S. Department of Defense to study a chemical compound with potential to fight osteoporosis and accelerate broken bone healing.

18 Aug 2011

Pegloticase can improve clinical outcomes of patients with chronic gout

Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of JAMA.

17 Aug 2011

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Green tea shows promise against two types of tumors, HHS

A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.

16 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been enrolled in its ESPRIT Phase III clinical trial of Epanova, in patients with hypertriglyceridemia (TG level greater than or equal to 200 and < 500 mg/dL) despite treatment with a statin.

16 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

Compound News and Research

Redesigned vancomycin can kill deadliest antibiotic-resistant bacteria

Scientists identify cellular protein that plays a critical role in Ebola virus infection

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

Trophos awarded US patent covering use of novel cardioprotective compound

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

No effective treatment yet for acute lung injury

New technique can detach sugars from carrier molecule, reattach them to drugs

Scientists discover mechanism that helps explain why stress causes DNA damage

VOA News examines new drug compound that shows broad-based efficacy in lab tests

Researchers turn their attention to Chagas disease as developed countries see rise in infection rates

Seven research teams across the U.S. to develop new drugs for nervous system disorders

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

Cortex second quarter net loss decreases to $356,000

IU scientist to investigate salubrinal drug against osteoporosis

Pegloticase can improve clinical outcomes of patients with chronic gout

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Green tea shows promise against two types of tumors, HHS

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

NAI reaches settlement with VPX over beta-alanine patent litigation

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News